-
How to Stay on Your Feet During Slippery Winter Conditions
Market news
drugs.comFebruary 13, 2017
Before you head outside to shovel the snow off your sidewalk this weekend, heed some safety advice so you don't slip on the ice and land in the ER.
-
Be Your Child's Valentine
Market news
drugs.comFebruary 13, 2017
Valentine's Day is two days away, and it's a great day to show your kids a little extra loving, child health experts say.
-
Zenith Technologies Strengthens Managed Services Biz
Market news
contractpharmaFebruary 13, 2017
David Staunton named director of global managed services
-
Impel Partners with Camargo for Development Programs
Market news
contractpharmaFebruary 13, 2017
Camargo to provide end-to-end regulatory consulting and development services
-
Cocoon Biotech Teams Up With Camargo
Market news
contractpharmaFebruary 13, 2017
Will focus on Cocoon's pipeline of osteoarthritis products
-
Werum IT, EIS in PAS-X Service Partnership
Market news
contractpharmaFebruary 13, 2017
EIS to support on-site implementation of Werum's PAS-X MES in Europe and U.S.
-
NewLink Genetics selects Cevec’s CAP Technologies to develop Zika vaccine
Market news
pharmaceutical-technologyFebruary 13, 2017
German company Cevec Pharmaceuticals has signed an agreement with NewLink Genetics for the use of its CAPGT and CAPGo cell lines in the development and commercialisation of products to treat Zika virus infections.
-
Natural Cycles fertility tracking app approved for contraception
Market news
pharmaceutical-technologyFebruary 13, 2017
Fertility tracking app Natural Cycles has been approved by global testing and certification provider Tüv Süd for contraception in the UK.
-
Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Can
Market news
americanpharmaceuticalreviewFebruary 13, 2017
The Merck Foundation has announced the selection of the six program sites and National Program Office forming the Alliance to Advance Patient-Centered Cancer Care (the Alliance).
-
1000 patient Phase III study required for Armetheon before FDA approval
Market news
europeanpharmaceuticalreviewFebruary 13, 2017
Armetheon has reached agreement with the US Food and Drug Administration (FDA) for a single 1000 patient final pivotal trial for its drug candidate, tecarfarin, prior to filing an NDA, which is currently projected to occur in 2019.
Pharma Sources Insight 08/2021
